Lakefront Biotherapeutics NV (GLPGN) Ratios
Lakefront Biotherapeutics NV Ratios
MX:GLPGN's free cash flow for Q1 2026 was $-78.74M. For the 2026 fiscal year, MX:GLPGN's free cash flow was decreased by $-123.00K and operating cash flow was $-78.61M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 20.15 | 9.97 | 9.02 | 8.11 | 8.58 |
| Quick Ratio | 20.00 | 9.81 | 8.84 | 8.01 | 8.55 |
| Cash Ratio | 0.57 | 0.19 | 0.39 | 0.97 | 3.94 |
| Solvency Ratio | 2.18 | 0.10 | 0.16 | -0.09 | -0.04 |
| Operating Cash Flow Ratio | -1.29 | -0.96 | -0.95 | -0.96 | -0.89 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 293.06 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 2.91B | $ 2.10B | $ 2.30B | $ 2.03B | $ 2.31B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.43 | 1.56 | 1.87 | 1.96 |
| Debt Service Coverage Ratio | 321.51 | -58.08 | 20.42 | -4.78 | -8.29 |
| Interest Coverage Ratio | 279.56 | -597.90 | -53.36 | -35.28 | -13.28 |
| Debt to Market Cap | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.13 | 0.18 | 0.17 | 0.45 | 0.60 |
| Net Debt to EBITDA | -0.16 | -1.21 | -3.62 | 14.57 | 21.86 |
| Profitability Margins | |||||
| Gross Profit Margin | 92.66% | 87.35% | 84.99% | 97.61% | 99.66% |
| EBIT Margin | 42.23% | -0.79% | 3.08% | -12.21% | -25.21% |
| EBITDA Margin | 46.89% | 15.72% | 18.10% | -6.60% | -20.82% |
| Operating Profit Margin | 42.23% | -68.33% | -36.82% | -52.94% | -34.15% |
| Pretax Profit Margin | 27.05% | -1.12% | 2.35% | -42.58% | -25.37% |
| Net Profit Margin | 28.85% | 26.88% | 88.31% | -43.14% | -25.87% |
| Continuous Operations Profit Margin | 28.72% | -0.47% | -1.66% | -14.13% | -25.87% |
| Net Income Per EBT | 106.65% | -2401.36% | 3763.50% | 101.32% | 101.97% |
| EBT Per EBIT | 64.06% | 1.64% | -6.37% | 80.42% | 74.28% |
| Return on Assets (ROA) | 9.42% | 1.79% | 4.86% | -4.60% | -2.42% |
| Return on Equity (ROE) | 9.92% | 2.56% | 7.57% | -8.63% | -4.74% |
| Return on Capital Employed (ROCE) | 14.43% | -4.96% | -2.25% | -6.35% | -3.58% |
| Return on Invested Capital (ROIC) | 14.43% | -2.06% | 1.59% | -6.34% | -3.57% |
| Return on Tangible Assets | 9.42% | 1.90% | 5.09% | -4.82% | -2.44% |
| Earnings Yield | 17.39% | 4.24% | 8.69% | -8.02% | -3.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 20.91 | 3.13 | 3.65 | 6.53 | 3.77 |
| Payables Turnover | 0.78 | 0.36 | 0.27 | 0.09 | 0.01 |
| Inventory Turnover | 3.63 | 0.68 | 0.49 | 0.23 | 0.08 |
| Fixed Asset Turnover | 13.79 | 2.24 | 1.90 | 3.28 | 3.53 |
| Asset Turnover | 0.33 | 0.07 | 0.06 | 0.11 | 0.09 |
| Working Capital Turnover Ratio | 0.38 | 0.09 | 0.07 | 0.13 | 0.11 |
| Cash Conversion Cycle | -350.05 | -371.11 | -515.40 | -2372.82 | -25387.09 |
| Days of Sales Outstanding | 17.46 | 116.64 | 99.97 | 55.87 | 96.81 |
| Days of Inventory Outstanding | 100.62 | 535.96 | 750.28 | 1599.27 | 4608.77 |
| Days of Payables Outstanding | 468.13 | 1023.71 | 1365.65 | 4027.96 | 30092.67 |
| Operating Cycle | 118.08 | 652.60 | 850.25 | 1655.14 | 4705.58 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.99 | -4.86 | -6.16 | -7.62 | -7.69 |
| Free Cash Flow Per Share | -3.20 | -6.10 | -6.45 | -8.18 | -8.58 |
| Dividend Paid and CapEx Coverage Ratio | -14.38 | -3.90 | -21.06 | -13.55 | -8.70 |
| Capital Expenditure Coverage Ratio | -14.38 | -3.90 | -21.06 | -13.55 | -8.70 |
| Operating Cash Flow Coverage Ratio | -28.49 | -27.30 | -42.31 | -22.85 | -18.76 |
| Operating Cash Flow to Sales Ratio | -0.18 | -1.16 | -1.69 | -0.99 | -1.04 |
| Free Cash Flow Yield | -11.42% | -23.01% | -17.45% | -19.79% | -17.42% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 5.75 | 23.68 | 11.51 | -12.46 | -25.70 |
| Price-to-Sales (P/S) Ratio | 1.66 | 6.34 | 10.17 | 5.38 | 6.65 |
| Price-to-Book (P/B) Ratio | 0.57 | 0.60 | 0.87 | 1.08 | 1.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.76 | -4.35 | -5.73 | -5.05 | -5.74 |
| Price-to-Operating Cash Flow Ratio | -9.36 | -5.46 | -6.00 | -5.43 | -6.40 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.36 | -0.06 | -0.17 | 0.43 |
| Enterprise Value Multiple | 3.38 | 39.12 | 52.55 | -66.85 | -10.08 |
| Enterprise Value | 1.76B | 1.70B | 2.28B | 2.23B | 1.02B |
| EV to EBITDA | 3.38 | 39.12 | 52.55 | -66.85 | -10.08 |
| EV to Sales | 1.59 | 6.15 | 9.51 | 4.41 | 2.10 |
| EV to Free Cash Flow | -8.37 | -4.22 | -5.36 | -4.15 | -1.81 |
| EV to Operating Cash Flow | -8.95 | -5.30 | -5.62 | -4.46 | -2.02 |
| Tangible Book Value Per Share | 49.10 | 40.40 | 39.43 | 35.16 | 39.44 |
| Shareholders’ Equity Per Share | 49.11 | 43.96 | 42.43 | 38.45 | 40.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.06 | 0.58 | 1.71 | -0.01 | -0.02 |
| Revenue Per Share | 16.88 | 4.18 | 3.64 | 7.69 | 7.40 |
| Net Income Per Share | 4.87 | 1.12 | 3.21 | -3.32 | -1.91 |
| Tax Burden | 1.07 | -24.01 | 37.64 | 1.01 | 1.02 |
| Interest Burden | 0.64 | 1.42 | 0.76 | 3.49 | 1.01 |
| Research & Development to Revenue | 0.37 | 1.22 | 1.01 | 1.02 | 1.01 |
| SG&A to Revenue | 0.10 | 0.35 | 0.39 | 0.37 | 0.20 |
| Stock-Based Compensation to Revenue | 0.00 | 0.07 | 0.24 | 0.18 | 0.15 |
| Income Quality | -0.62 | -4.32 | -1.92 | 2.30 | 4.88 |
Currency in EUR